GalNAc-siRNA Conjugates: Targeted Gene Therapy for Liver Diseases

Delivering nucleic acids as therapeutic drugs requires solving multiple interconnected challenges. First, unmodified nucleic acids are rapidly degraded in biological fluids by nucleases. Second, even if they survive, their large size and negative charge prevent crossing cell membranes. Third, once inside cells, they must escape from degradative endosomes to reach the cytoplasm. The solution involves ionizable lipids that become positively charged at low pH during formulation, enabling efficient encapsulation, but remain neutral at physiological pH, reducing toxicity. This breakthrough allowed researchers to develop lipid nanoparticles capable of protecting nucleic acids during circulation, facilitating cellular uptake, and enabling endosomal escape through membrane destabilization.

Nucleic acids offer unique advantages as therapeutics because they can address all levels of the central dogma of biology—from genomic DNA editing (CRISPR) to mRNA targeting (antisense/siRNA) to protein and receptor binding (aptamers). Despite this versatility, linear nucleic acids face three major barriers: poor cellular uptake due to electrostatic repulsion between negatively charged phosphate backbones and cell membranes, rapid degradation by nucleases in blood/serum within minutes, and potential immune responses. These limitations explain why nucleic acids haven't dominated the drug market despite their theoretical promise.

Nucleic acids face three major barriers: rapid enzymatic degradation, inability to cross cell membranes, and electrostatic repulsion at physiological pH. Lipid nanoparticles address these challenges by protecting against nucleases, enabling cellular uptake, and preventing protein interactions. The first approved mRNA vaccines utilized this encapsulation strategy. Microfluidic devices enable precise nanoparticle production with consistent size (~150 nm) and high encapsulation efficiency, essential for reliable therapeutic delivery.

Despite their therapeutic promise, RNA-based drugs face fundamental delivery barriers rooted in 3.5 billion years of evolutionary adaptation. Four major barriers exist: (1) High negative charge prevents crossing the lipid bilayer membrane; (2) Ubiquitous RNases degrade RNA rapidly; (3) Kidneys filter out charged molecules; (4) Innate immune system recognizes naked nucleic acids as invaders. These barriers represent nature's successful defense against foreign genetic material. Small molecules like AZT ($500) can cross membranes passively, but adding even one phosphate charge prevents passage. The contrast highlights why nucleic acid therapeutics require sophisticated delivery solutions despite their superior targeting capabilities.

Receptor-mediated endocytosis is a highly specific process by which cells internalize particular molecules from the extracellular fluid. Receptors on the cell surface bind to specific ligands, and this binding triggers the formation of coated pits that invaginate to form vesicles. The vesicles then fuse with endosomes, where the ligands are sorted for delivery to lysosomes or recycling back to the cell surface. This process allows cells to efficiently internalize specific molecules even when they are present in low concentrations.

Receptor-mediated endocytosis begins when a specific molecule (ligand) binds to a receptor on the cell membrane. This binding triggers the formation of a coated pit that invaginates to form a vesicle containing the bound ligand.

Receptor-mediated endocytosis is a selective form of fluid phase endocytosis where specific cell surface receptors bind extracellular ligands before being internalized. The clathrin-coated pit spontaneously forms and invaginates, and if receptors bound to ligands happen to be present in the pit, they get trapped and internalized together. This process allows cells to concentrate specific molecules from the extracellular environment. The coated pit then pinches off to form a clathrin-coated vesicle that will deliver its cargo to endosomes.

Receptor-mediated endocytosis is a highly specific process used by animal cells to internalize particular macromolecules. Specific receptor proteins on the extracellular surface of the plasma membrane bind to target molecules. This binding triggers the formation of a coated pit (a coated region with clathrin proteins), which then invaginates to form a coated vesicle that brings the bound molecule into the cell. An example is cholesterol uptake.

Receptor-mediated endocytosis is the primary cellular mechanism for internalizing macromolecules that cannot cross the cell membrane independently. This process serves three critical functions: internalization of nutrients and signaling molecules for cellular metabolism, generation of intracellular signals coordinating cellular responses including neurotransmission and immune surveillance, and regulation of receptor numbers on the cell surface. The LDL receptor is a cup-shaped protein embedded in the plasma membrane with a stem extending into the cytoplasm. When LDL binds to its receptor, the complex forms a coated pit structure that buds inward to form a vesicle. Coated pits provide mechanical rigidity to prevent vesicle rupture during transport. After vesicle formation, hydrogen ion pumps lower the internal pH, facilitating receptor-ligand dissociation. The dissociated receptors are recycled back to the cell surface, while ligands are directed to lysosomes for degradation. Receptors are classified into two classes: Class 1 receptors bind to ligands first, then migrate to coated pits; Class 2 receptors form coated pits first, then ligands bind. Both classes follow similar subsequent steps involving vesicle formation, acidification, and receptor recycling. Coated pits form continuously every 2-3 minutes, covering 1-5% of the membrane. The process matures through early and late endosomes, with receptors recycled back to the cell surface while ligands proceed to lysosomes. LDL receptors complete a round trip in approximately 12 minutes and can undergo 150 cycles before degradation.

The asialoglycoprotein receptor is found on the surface of endothelial cells of the liver, macrophages, and dendritic cells. It is a clearance receptor that binds glycoproteins terminated in N-acetylglucosamine or mannose, removing them from circulation. The receptor has eight C-type CRDs that bind mannose, with domain 4 being particularly important. It binds released lysosomal enzymes at sites of inflammation or tissue damage to remove them from circulation. It also has an R-type CRD that binds four sulfated galactose, a modification found on pituitary hormones like lutropin and thyrotropin, regulating their levels.

The asialoglycoprotein receptor (ASGPR) on hepatocytes recognizes sugar-like residues called N-acetylgalactosamine. This discovery revolutionized RNA-based therapies by enabling efficient liver targeting. By tagging drugs with this sugar complex, small amounts of drug can be delivered subcutaneously and reach the liver within approximately four hours, allowing for effective hepatic targeting of PCSK9 mRNA without requiring large injection volumes.

The asialoglycoprotein receptor (ASGPR), a C-type lectin with H1 and H2 subunits, recognizes multivalent carbohydrates and mediates clathrin-dependent hepatocyte uptake. With ~500,000 receptors per hepatocyte, it represents an ideal liver-targeting platform. Analysis of over 400 patient samples reveals dynamic expression changes: cirrhotic livers show elevated ASGPR expression, presenting opportunities for anti-cirrhotic therapies, while hepatocellular carcinoma shows decreased receptor expression and altered localization. These findings highlight the importance of considering disease-stage-specific receptor expression when developing targeted nanomedicines. An ideal target receptor requires abundant expression, predominant cell-type specificity, internalization properties, and consideration of pathological changes. Natural multivalent glycans isolated via enzymatic cleavage offer superior geometrical arrangement and binding efficiency compared to synthetic alternatives. Preclinical model selection must account for species differences in receptor expression and anatomical features like fenestration size.

The asialoglycoprotein receptor (ASGPR) is a liver-specific lysosomal trafficking receptor binding terminal N-acetylgalactosamine and galactose residues. It has been used for hepatocyte-specific delivery of antisense oligonucleotides in approved therapies. Trigalactosyl dendrimers terminating with cyclooctynes were synthesized for ASGPR targeting. Compared to M6PR-targeting LYTACs, ASGPR-targeting LYTACs showed superior uptake efficiency in hepatocytes. Despite differences in uptake kinetics, both receptor types achieved comparable EGFR degradation efficiency in cells expressing both receptors, suggesting that once bound to the target, the specific trafficking details become less critical.

Hepatocytes are large polyhedral cells (20-30 μm) with specialized membranes: sinusoidal-facing membranes absorb plasma components, while bile-facing membranes secrete bile. Membrane specialization determines drug elimination pathways—some metabolites go to bile (fecal elimination), others return to blood (urinary elimination). Hepatocytes contain ~800-1000 mitochondria, lysosomes, peroxisomes, rough ER (protein synthesis: albumin, coagulation factors), and smooth ER (lipid metabolism, hormone modification). Ito cells store vitamin A and fat; chronic inflammation activates them to myofibroblasts producing collagen, leading to fibrosis and cirrhosis. The liver performs four major functions: exocrine (bile secretion: conjugated bilirubin, phospholipids, cholesterol, bile salts, IgA); endocrine (plasma proteins: albumin, alpha-globulins, fibrinogen, prothrombin; coagulation factors; lipoproteins: VLDL, LDL, HDL); metabolic (glycogen storage/release to stabilize blood glucose, gluconeogenesis from amino acids/fatty acids); detoxification (biotransformation of drugs, hormones, toxins).